Michelle Griffin, Director (Chair, Audit Committee) at Adaptive Biotechnologies Corp.. Biography, career history and compensation sourced from SEC proxy filings.
About
Michelle Griffin has served on Adaptive Biotechnologies' board of directors since March 2019 and chairs the Audit Committee. She previously served on the boards of Acer Therapeutics, HTG Molecular Diagnostics, Chinook Therapeutics, PhaseRx, OncoGenex Pharmaceuticals (now Achieve Life Sciences) and Sonus Pharmaceuticals, often as audit committee chair. Ms. Griffin held senior financial and operating roles including Executive Vice President, Operations and Chief Financial Officer at OncoGenex Pharmaceuticals (2011-2013), Acting Chief Executive, Senior Vice President and Chief Operating Officer and earlier Chief Financial Officer at Trubion Pharmaceuticals (2006-2010), Senior Vice President and Chief Financial Officer of Dendreon Corp. (2005-2006) and Chief Financial Officer of Corixa Corp (1997-2005). She holds a BS in marketing from George Mason University and an MBA from Seattle University.
Roles
Adaptive Biotechnologies Corp.
Director (Chair, Audit Committee) · Current role
March 2019–present
OncoGenex Pharmaceuticals, Inc.
Executive Vice President, Operations and Chief Financial Officer
January 2011 - April 2013
Trubion Pharmaceuticals, Inc.
Acting Chief Executive, SVP and Chief Operating Officer
November 2009 - October 2010
Trubion Pharmaceuticals, Inc.
Chief Financial Officer
January 2006 - November 2009
Dendreon Corp.
Senior Vice President and Chief Financial Officer
August 2005 - January 2006
Corixa Corp.
Chief Financial Officer
October 1997 - August 2005
External Roles
Acer Therapeutics, Inc.
Director (Audit Committee Chair)
—
HTG Molecular Diagnostics, Inc.
Director (Audit Committee Chair)
—
Chinook Therapeutics
Former director
—
PhaseRx, Inc.
Former director
—
OncoGenex Pharmaceuticals / Achieve Life Sciences
Former director
—
Sonus Pharmaceuticals
Former director
—
Director Compensation
FY 2025
Fees earned or paid in cash
$80,000
Component$60,000 annual cash retainer plus any lead-director/committee-chair fees earned in FY2025
Option awards
$124,998
ComponentAnnual stock option grant, ASC 718 grant-date fair value
Stock awards
$124,999
ComponentAnnual RSU grant, ASC 718 grant-date fair value